September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
1 citations
,
July 2024 in “Journal of Assisted Reproduction and Genetics” Finasteride causes reproductive changes in male rats.
3 citations
,
January 2010 in “Actas Dermo-Sifiliográficas” Psychotropic drugs can help treat skin conditions affected by mental health, but dermatologists must use them carefully due to side effects and patient concerns.
35 citations
,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
July 2020 in “Journal of the American Academy of Dermatology” Spironolactone does not increase the risk of breast cancer recurrence.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
Neonatal allopregnanolone and stress affect behavior differently in adolescence and adulthood.
9 citations
,
July 2011 in “The Journal of Sexual Medicine” Hair loss drugs like finasteride may cause lasting sexual and mood side effects, and more research is needed to understand these risks.
June 2019 in “Reactions Weekly” July 2025 in “Journal of Investigative Dermatology” Spironolactone can safely lower blood pressure in patients on other blood pressure medications, but may slightly increase the risk of low blood pressure.
Early NAS level changes affect alcohol consumption vulnerability.
19 citations
,
April 2017 in “Synapse” Blocking allopregnanolone production in mice makes them more anxious after stress, but this can be reversed with a drug that mimics allopregnanolone.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Higher doses of spironolactone may improve acne in PCOS patients, but side effects are a concern.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
October 1990 in “Pediatric Research” Nocturnal calcium infusions improved a boy's severe rickets without causing hair loss.
17 citations
,
November 2017 in “Experimental physiology” Breathing in newborn rats is affected differently by hormones based on their sex.
11 citations
,
July 2023 in “Applied Nanoscience”
7 citations
,
December 2017 in “Journal of the European Academy of Dermatology and Venereology” Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.
12 citations
,
January 1993 in “PubMed”
1 citations
,
September 2016 in “Actas Dermo-Sifiliográficas” 5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.
32 citations
,
September 2010 in “Stress” Neurosteroids help protect fetal brains from asphyxia damage.
35 citations
,
April 2013 in “Sexual medicine reviews” 5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
7 citations
,
June 2016 in “Bone Research” A Chinese family had a child with a specific gene mutation causing vitamin D-resistant rickets, but the child improved with calcium and low-dose calcitriol.
June 2025 in “Pharmaceuticals” Finasteride use may increase suicidality risk, especially in young men.
6 citations
,
January 2018 in “Pharmacoepidemiology and Drug Safety” Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
2 citations
,
June 1986 in “Journal of Clinical Pharmacy and Therapeutics” Metal binding to sodium valproate may be linked to hair loss in epilepsy patients.